144 ·Filed Jun 29, 2026

ANAB

ANAPTYSBIO, INC
BEARISH
Impact 6/10
Horizondays Processed3mo ago SEC0001950047-26-006580
Form 144 — notice of proposed sale of securities
Actionable Insight ▼ Bearish

The sustained insider selling by an officer is a strong bearish signal. Traders should consider reducing positions or hedging ahead of potential negative news. Monitor for upcoming earnings or pipeline updates that could trigger further downside.

DirectionBearish
Confidencehigh
Horizondays
Final — all horizons settled through T+60d ⚠ clustered
ANAB ▼ -24.79% at T+60d
SHORT call ✓ call won +24.79% · α vs SPY +28.35% · entry $67.50 → $50.77
Entry anchored
Jun 29, 03:59 PM ET
via exchange tick
T+1d
-3.07%
call +3.07% · α +2.93%
$65.43
settled 3mo ago
T+5d
-7.69%
call +7.69% · α +8.29%
$62.31
settled 3mo ago
T+20d
-20.58%
call +20.58% · α +19.55%
$53.61
settled 2mo ago
T+60d
-24.79%
call +24.79% · α +28.35%
$50.77
settled 9d ago

Price Chart

Loading chart...

Executive Summary

Officer Dennis Mulroy filed a Form 144 to sell 9,476 shares (~$601K) of AnaptysBio, continuing a heavy selling pattern of over 300,000 shares in the past month. This persistent insider selling by a key officer is a bearish signal, suggesting potential negative catalysts ahead.

Key Facts

  • Officer Dennis Mulroy intends to sell 9,476 shares of common stock, estimated value $601,213.35.
  • Mulroy has sold over 300,000 shares in the past month (since May 15, 2026) across numerous transactions.
  • The proposed sale follows a stock option exercise, resulting in dilution and insider cash-out.
  • Filing date: June 29, 2026; broker: Morgan Stanley Smith Barney LLC.

Financial Impact

Proposed sale of $601K; cumulative insider selling in past month exceeds $15M based on transaction values listed.

dilutioninsider ownership

Risk Factors

  • Continued insider selling could pressure the stock price.
  • Potential negative catalyst (e.g., clinical trial setback, guidance miss) may be imminent.
  • High analyst bullishness (94% buy) contrasts with insider behavior, creating divergence risk.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (17 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-006580
Document: 0001950047-26-006580-index.html0001950047-26-006580
Document: 0001950047-26-006580.txt0001950047-26-006580
24 reports for ANAB
Performance horizon
65% Hit rate 11 of 17 directional calls best @ T+60▲ +41.26%Mar 3, 2026
Filters
Rows
Reports for ANAB — sortable, filterable
TypeNow
Aug 12, 2026
7w ago
Institutional Cluster
BULLISH ★ 5/10
$56.02 $53.87▼ −3.84%▼ −2.09%$48.53 (−13.37%)
Jun 29, 2026
13w ago
144
BEARISH ★ 6/10
$67.50 $53.61▲ +20.58%▲ +19.55%$48.53 (+28.10%)
Jun 29, 2026
13w ago
DEFA14A
NEUTRAL ★ 2/10
$67.50 $53.61▼ −20.58%▼ −19.55%$48.53 (−28.10%)
Jun 26, 2026
14w ago
144
BEARISH ★ 6/10
$65.97 $54.15▲ +17.92%▲ +17.64%$48.53 (+26.44%)
Jun 22, 2026
14w ago
8-K
NEUTRAL ★ 2/10
$59.43 $50.29▼ −15.38%▼ −16.54%$48.53 (−18.34%)
Jun 17, 2026
15w ago
144
BEARISH ★ 5/10
$57.51 $54.15▲ +5.84%▲ +6.38%$48.53 (+15.61%)
Jun 15, 2026
15w ago
144
BEARISH ★ 6/10
$57.61 $62.51▼ −8.51%▼ −8.31%$48.53 (+15.76%)
Jun 11, 2026
16w ago
144
BEARISH ★ 6/10
$56.07 $66.39▼ −18.41%▼ −16.63%$48.53 (+13.45%)
Jun 10, 2026
16w ago
144
BEARISH ★ 5/10
$54.24 $66.59▼ −22.77%▼ −20.88%$48.53 (+10.53%)
Jun 8, 2026
16w ago
144
BEARISH ★ 5/10
$51.63 $67.33▼ −30.40%▼ −28.95%$48.53 (+6.00%)
Showing 10 of 24

US Market Status

Market Closed — Opens Mon (64h 22m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access